Merger of BerGenBio and Oncoinvent completed

Oslo, 29 October 2025 – Reference is made to the previous stock exchange announcements made in connection with the combination of BerGenBio ASA and Oncoinvent ASA ("**Oncoinvent**") through a statutory triangular merger (the "**Merger**"), including the announcements made on 4 August 2025 regarding approval of the Merger by the extraordinary general meetings of the two companies. Reference is further made to the stock exchange announcement made on 24 October 2025 regarding key dates for completion of the Merger and the stock exchange announcement made on 28 October 2025 regarding the approval and publication of the prospectus (the "**Prospectus**") prepared in connection with the Merger and the contemplated rights issue in the combined company.

Completion of the Merger has today been registered with the Norwegian Register of Business Enterprises. Consequently, Oncoinvent has been dissolved and the name of BerGenBio ASA has been changed to Oncoinvent ASA (the "**Combined Company**"). Following the issuance of the 117,554,012 merger consideration shares (the "**Merger Shares**") to be delivered to former shareholders of Oncoinvent, the new share capital of the Combined Company is NOK 156,641,128, divided into 156,641,128 shares, each with a nominal value of NOK 1.

The Merger Shares will be distributed on a pro rata basis to the former shareholders of Oncoinvent as of 29 October 2025 (as registered in Euronext Securities Oslo on 31 October 2025), and are expected to be delivered in Euronext Securities Oslo on or about 3 November 2025.

For further details on the Merger, please see the announcements mentioned above and the Prospectus.

The Combined Company will give an update on the Merger as well as a quarterly update in a live virtual presentation on 4 November 2025 at 08:30 (CET). The presentation will be broadcasted live on https://channel.royalcast.com/landingpage/hegnarmedia/20251104_9/. The Combined Company will give a status on the ongoing phase 2 ovarian cancer study including a status on recruitment of 20 patients by the end of the third quarter of 2025, as well as a financial status.

This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

About Oncoinvent ASA

Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product candidate, Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting micro-metastases post-surgery, harnessing the benefits of modern radiopharmaceuticals without the complexities of biological targeting. Oncoinvent ASA is investigating the safety and efficacy of Radspherin® in a clinical development program in two indications. One Phase 1 trial and one Phase 1/2a trial have been completed and one randomized Phase 2 trial is currently ongoing in the US, UK and Europe. Early clinical efficacy data are highly encouraging, and no serious toxicity or safety concerns have been reported to date. The Oncoinvent ASA team consists of approx. 40 employees and runs a state-of-the-art manufacturing facility to produce drug products for clinical trials in Nydalen, Oslo. Oncoinvent ASA is listed on the Euronext Oslo Børs.

Forward-looking statement:

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that the Combined Company's plans, estimates, or expectations will be achieved. These forward-looking statements represent the Combined Company's expectations as of the date of this press release, and the Combined Company disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers.